Landmark trial shows aspirin does not prevent cognitive decline in healthy elderly PRESS RELEASE: 1st April 2020 – Melbourne Researchers at Monash University and the Berman Center for Outcomes and Clinical Research in the US, have found that daily aspirin does not reduce the risk of Alzheimer’s disease, mild cognitive impairment, or cognitive decline…
Details
FOR PARTICIPANTS: Important information about ASPREE-XT and the Coronavirus (COVID-19) In light of public health recommendations to help slow the spread of Coronavirus (COVID-19) in the community, ASPREE-XT will be temporarily replacing annual face-to-face study visits with a phone call. This decision, which took effect as of Monday 23rd March 2020, will continue until further notice.…
Details
IT’S A WRAP FOR 2019! While we’d say that all study-related news and events were important, the most significant was the welcomed mid-year announcement that the NIA (National Institute on Aging) in the US would be funding the follow-up ASPREE-XT (eXTension) study for a further five years. Funding has ensured that our participants can…
Details
Impact of ASPREE trial on public health recognised. ASPREE researchers acknowledge the contribution of participants, GPs and fellow team members to the world-first trial. We are pleased to share details and photos of three Australian research awards recently won by the ASPREE study for its significance to public health. Monash University Dean’s Award…
Details
Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin. ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of ASPREE (low dose…
Details
Thanks to the American College of Cardiology, we are pleased to share this physician-penned article on the importance of the ASPREE study and the implications that study findings have on healthcare of older people around the world. The ASPREE Aftermath: A Geriatric Perspective on the Role of Aspirin in Older Adults Oct 11,…
Details
Welcome to our US NCI colleagues ASPREE investigators welcomed members from the National Cancer Institute (NCI) to the School of Public Health and Preventive Medicine, Monash University late last month. The NCI, a branch of the National Institutes of Health in the USA, funds ACES, the ASPREE Cancer Endpoints Study to better understand the…
Details
Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people from shutterstock.com John McNeil, Monash University Taking low-dose aspirin daily doesn’t preserve good health or delay the onset of disability or dementia in healthy older people. This was one finding from our seven-year study that included more than 19,000 older people from Australia and the…
Details
ASPREE-XT: follow-up aspirin & ageing research Thanks to a funding boost from the NIA (National Institute on Aging), we are delighted to announce that study visits will continue in 2018 as part of the new ASPREE-XT ( XT is shortened for eXTension) study. A staggering 95% of ASPREE participants had indicated, prior to the…
Details
It seems 2017 was the year of the study updates! We’ve not quite been everywhere – but we have held study updates in many places this year. And it’s been fun. From Wollongong to Burnie, members of our team were delighted to meet thousands of ASPREE participants and guests during 24 presentations held across…
Details© 2019 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy